DNL593 News

Latest Articles

• Takeda Terminates Denali Partnership and Returns Dementia Asset Amid $1.26 Billion Strategic Restructuring

  Published: Apr 7, 2026

  Section: US & Canada

  Takeda has ended its neurodegenerative disease collaboration with Denali Therapeutics, returning the full rights for the dementia candidate DNL593. The move is part of a massive re...